Epithelioid Sarcoma — Variants & evidence

Epithelioid Sarcoma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
SMARCB1 Deletion1
Tazemetostat	Predictive	A	Supports Sensitivity Response	4	submitted	EID9992 In this phase II, multicenter study of tazemetostat (EZH2 inhibitor) in adults with INI1-negative tumors or relapsed/refractory synovial sarcoma, subjects were enrolled into one of 7 cohorts. Cohort #… (full text at CIViC) PMID 33035459 · Gounder et al., 2020 · Open in CIViC	civic
SMARCB1 Loss2
(oncogenic)	Oncogenic	B	Supports Oncogenicity	3	accepted	EID9993 This study aimed to characterize the spectrum of SMARCB1 gene abnormalities in epithelioid sarcoma. 19/21 patients were SMARCB1 immunohistochemistry-negative. Multiplex ligation dependent probe amplif… (full text at CIViC) PMID 23060122 · Sullivan et al., 2013 · Open in CIViC	civic
Tazemetostat	Predictive	C	Supports Sensitivity Response	2	submitted	EID11181 In the dose expansion of phase I pediatric trial (NCT02601937) of the EZH2 inhibitor tazemetostat, the overall response in 9 patients with SMARCB1-deficient epithelioid sarcoma was 22%, with 1 complet… (full text at CIViC) Open in CIViC	civic

Data updated 2 hours agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.